Industry Eyes NDI Notification Common Ground With Gottlieb-Led FDA
This article was originally published in The Rose Sheet
Executive Summary
CHPA and CRN look forward to working with FDA to develop a path for the identification of pre-DSHEA ingredients, but say the FDA’s revised draft guidance for new dietary ingredient notifications still hampers innovation.
You may also be interested in...
US Supplement Market Growth: Is The Industry In Its Own Way?
Longtime supplement industry attorney Scott Bass says supplement manufacturers should work with FDA as an ally, including registering products with the agency pre-market, while FDA's second-in-command for supplement industry oversight, Robert Durkin, says the agency is not interested in preventing more safe products from reaching the market.
FDA Plans For Soy Health Claims, Pyridoxamine's Use Questioned By CRN, NPA
FDA’s proposed rule to revoke soy protein heart health ignores research supporting the claims and cites evidence that isn't compelling, CRN an NPA say in comments to the agency. CRN also submits comments supporting an ingredient firm's petition asking FDA to remove any uncertainty about the of use of pyridoxamine as a dietary ingredient.
GAO Memory Supplement Review Recalls FDA's Regulatory Challenges
GAO recommends better cooperation between FDA and FTC and more public outreach are key to preventing consumers from believing noncompliant cognitive benefit claims for supplements.